微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 53.26% | -5.43% | -12.81% | 70/157 | 48.88% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 61.08% | 12.29% | 4.67% | 52/157 | 50.55% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 58.36% | 6.39% | 1.11% | 55/157 | 50.61% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 57.71% | 6.84% | 2.49% | 57/157 | -2.2% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 56.31% | 6.86% | 3.52% | 60/157 | 14.82% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 54.4% | 2.36% | -0.83% | 63/157 | 31.96% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 54.85% | 26.78% | 1.54% | 69/157 | 51.88% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 54.02% | 25.81% | 2.5% | 68/157 | 22.51% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 52.7% | 26.05% | -0.83% | 74/157 | 33.12% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 53.14% | 35.39% | 22.83% | 67/157 | 51.76% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 43.26% | 12.11% | 0.77% | 98/157 | 51.61% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 42.93% | 8.94% | 2.7% | 96/157 | 32.47% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 41.81% | 9.54% | 6.52% | 99/157 | 38.42% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 39.25% | -3.04% | 1.7% | 99/157 | 52.97% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 38.59% | -13.2% | -2.08% | 104/157 | 53.83% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 39.41% | -12.58% | 3.27% | 99/157 | 5.64% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 38.17% | -12.87% | -5.72% | 104/157 | 20.99% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 40.48% | -9.16% | -8.96% | 93/157 | 54.39% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 44.46% | -6.62% | -1.38% | 90/157 | 55.2% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 45.08% | -6.77% | 2.93% | 80/157 | 46.77% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 43.8% | -3.81% | -1.7% | 86/157 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 44.56% | -10.04% | -6.41% | 76/157 | 54.13% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 47.61% | -0.53% | -1.54% | 83/157 | -148.64% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 48.36% | 0.45% | 6.19% | 71/157 | 56.43% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 45.54% | 3.93% | -8.07% | 84/157 | 54.17% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 49.53% | 6.68% | 3.48% | 65/157 | 55.17% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 47.87% | -2.1% | -0.57% | 82/157 | -1242.15% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 48.14% | -0.24% | 9.87% | 63/157 | 55.23% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 43.82% | -5.6% | -5.64% | 72/157 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 46.43% | 1.89% | -5.03% | 64/157 | 51.07% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 48.89% | -5.56% | 1.32% | 73/157 | -211.97% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 48.26% | -6.86% | 3.97% | 58/157 | 54.14% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 46.41% | -9.82% | 1.85% | 62/157 | 53.53% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 45.57% | -9.21% | -11.97% | 60/157 | 54.16% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 51.77% | -19.99% | -0.08% | 60/157 | 52.55% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 51.81% | -19.38% | 0.66% | 43/157 | 49.09% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 51.47% | -18.39% | 2.54% | 41/157 | 47.91% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 50.19% | -18.14% | -22.42% | 39/157 | 46.94% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 64.7% | -3.7% | 0.68% | 24/157 | 48.46% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 64.27% | -3.83% | 1.9% | 19/157 | 46.19% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 63.07% | -3.94% | 2.86% | 22/157 | 46.26% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 61.32% | 3.83% | -8.74% | 19/157 | 43.86% | 贝达药业 | 97.01% | 行业排名> |